Search

Your search keyword '"Price TJ"' showing total 492 results

Search Constraints

Start Over You searched for: Author "Price TJ" Remove constraint Author: "Price TJ"
492 results on '"Price TJ"'

Search Results

1. The use of metformin is associated with decreased lumbar radiculopathy pain

2. The use of metformin is associated with decreased lumbar radiculopathy pain [Erratum]

3. The Management of Unresectable, Advanced Gastrointestinal Stromal Tumours

4. VEGF-A, VEGFR1 and VEGFR2 single nucleotide polymorphisms and outcomes from the AGITG MAX trial of capecitabine, bevacizumab and mitomycin C in metastatic colorectal cancer

5. Anti-angiogenic properties of ginsenoside rg3 epimers: In vitro assessment of single and combination treatments

6. In vitro synergistic inhibition of HT-29 proliferation and 2H-11 and HUVEC tubulogenesis by bacopaside I and II is associated with Ca²⁺ flux and loss of plasma membrane integrity

8. Anti-cancer effects of an optimised combination of ginsenoside rg3 epimers on triple negative breast cancer models

9. Vigilance for carcinoid heart disease is still required in the era of somatostatin analogues: Lessons from a case series

10. Treatment and outcomes of metastatic colorectal cancer patients in public and private hospitals: results from the South Australian Metastatic Colorectal Cancer Registry

11. Anti-Angiogenic Properties of Ginsenoside Rg3

12. Prognostic significance of postsurgery circulating tumorDNAin nonmetastatic colorectal cancer: Individual patient pooled analysis of three cohort studies

13. KRAS(G12C) Inhibition with Sotorasib in Advanced Solid Tumors

14. Breaching borders : an investigation into painting the news

15. Ginsenoside Rg3: Potential Molecular Targets and Therapeutic Indication in Metastatic Breast Cancer

16. Bacopasides I and II act in synergy to inhibit the growth, migration and invasion of breast cancer cell lines

18. Bumetanide-derived aquaporin 1 inhibitors, AqB013 and AqB050 inhibit tube formation of endothelial cells through induction of apoptosis and impaired migration in vitro

20. SPAR - a randomised, placebo-controlled phase II trial of simvastatin in addition to standard chemotherapy and radiation in preoperative treatment for rectal cancer: an AGITG clinical trial.

21. Challenges of international oncology trial collaboration-a call to action.

22. Phase II study of everolimus (RAD001) monotherapy as first-line treatment in advanced biliary tract cancer with biomarker exploration: the RADiChol Study

23. The effect of anti-angiogenic agents on overall survival in metastatic oesophago-gastric cancer: A systematic review and meta-analysis

24. Reducing the polyp burden in serrated polyposis by serial colonoscopy: the impact of nationally coordinated community surveillance

25. Findings in young adults at colonoscopy from a hospital service database audit

26. Hope, optimism and survival in a randomized trial of chemotherapy for metastatic colorectal cancer

27. Panitumumab added to docetaxel, cisplatin and fluoropyrimidine in oesophagogastric cancer: ATTAX3 phase II trial

30. Does the Chemotherapy Backbone Impact on the Efficacy of Targeted Agents in Metastatic Colorectal Cancer? A Systematic Review and Meta-Analysis of the Literature

31. Correlation of extended RAS and PIK3CA gene mutation status with outcomes from the phase III AGITG MAX STUDY involving capecitabine alone or in combination with bevacizumab plus or minus mitomycin C in advanced colorectal cancer

32. Rising incidence of early-onset colorectal cancer in Australia over two decades: Report and review

33. Vascular endothelial growth factor D expression is a potential biomarker of bevacizumab benefit in colorectal cancer

34. The role of biological therapy in metastatic colorectal cancer after first-line treatment: a meta-analysis of randomised trials

35. Can we accurately report PTEN status in advanced colorectal cancer?

36. Epiregulin gene expression as a biomarker of benefit from cetuximab in the treatment of advanced colorectal cancer

37. Prognostic impact and the relevance of PTEN copy number alterations in patients with advanced colorectal cancer (CRC) receiving bevacizumab

38. Final results of AGITG ATTAX3 study: Randomized phase II study of weekly docetaxel (T), cisplatin, and fluoropyrimidine (F) with or without panitumumab (P) in advanced esophagogastric (OG) cancer

39. The effect of different dosing regimens of motesanib on the gallbladder: a randomized phase 1b study in patients with advanced solid tumors

40. Safety and pharmacokinetics of motesanib in combination with gemcitabine for the treatment of patients with solid tumours

41. Capecitabine and mitomycin C as third-line therapy for patients with metastatic colorectal cancer resistant to fluorouracil and irinotecan.

44. Critical evaluation of the colocalization between calcitonin gene-related peptide, substance P, transient receptor potential vanilloid subfamily type 1 immunoreactivities, and isolectin B4 binding in primary afferent neurons of the rat and mouse.

46. Response to Cetuximab With or Without Irinotecan in Patients With Refractory Metastatic Colorectal Cancer Harboring the KRAS G13D Mutation: Australasian Gastro-Intestinal Trials Group ICECREAM Study

47. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer

48. Colorectal cancer treatment and survival over three decades at four major public hospitals in South Australia: trends by age and in the elderly

49. Brain metastasis in advanced colorectal cancer: Results from the South Australian metastatic colorectal cancer (SAmCRC) registry

50. Gemcitabine and carboplatin in carcinoma of unknown primary site (CUP) in elderly patients: Analysis of a phase 2 Adelaide Cancer Trials and Education Collaborative (ACTEC) study

Catalog

Books, media, physical & digital resources